drugset / Trial / NCT06243458
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Phase 2
Active not recruiting
41 enrolled
GCP-Service International West GmbH
European Myelodysplastic Neoplasms Cooperative Group · collabMedical University of Warsaw · collabRyvu Therapeutics SA · collabSaint-Louis Hospital, Paris, France · collabUniversity of Florence · collabUniversity of Salamanca · collabUniversitätsklinikum Leipzig · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate orally administered RVU120, a novel small molecule Cyclin-dependent Kinase (CDK) 8/19 inhibitor, in terms of erythroid hematologic improvement (HI-E) and safety in participants with lower-risk myelodysplastic syndrome (MDS). Responding patients are eligible to continue treatment until loss of response/disease progression.
Timeline
- Start
- 2024-09-10
- Primary completion
- 2026-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEL-120 FREE BASE | Small molecule | — | Oral |